On January 16, 2026, Profusa, Inc. launched its Healthcare Research version of the Lumee tissue oxygen monitoring system targeting contract research organizations (CROs). The research-use-only (RUO) kits and service-enabled platform are immediately available, marking the company’s first commercial revenue for this product line. This strategic offering allows CRO partners to integrate continuous, real-time tissue oxygen measurements into preclinical pharmacology, toxicology studies and advanced in vitro and organ-on-chip models with minimal implementation risk.

Profusa expects the RUO Lumee system to drive near-term service-based revenue by tapping into the global CRO market, estimated at $47.9 billion in 2025 and projected to grow at a 7% compound annual growth rate through 2034. The technology’s ability to provide predictive, biologically relevant data—such as tissue oxygenation dynamics in wound healing and tumor microenvironments—positions the company to capitalize on accelerating R&D investment and regulatory momentum around new approach methodologies in drug development.

To support commercialization efforts, Profusa appointed Sean Givens as Head of Government and Healthcare Research Business. Givens brings over 20 years of government accounting and contracting expertise, consumer electronics and medical device operations experience, and a proven track record from his tenure as co-founder and COO of MIODx. His leadership is expected to fast-track partnerships with CROs and drive revenue growth by leveraging the validated, ready-to-ship sensor platform.